drugset / Trial / NCT02391038
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effects of MLN0264 in previously treated Asian participants with Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC).
Timeline
- Start
- 2014-12
- Primary completion
- 2015-10
- Completion
- 2015-10
Outcome
Outcome not reported
Stopped: “The study was terminated because preliminary PK and overall clinical data demonstrated compelling similarity between Western and Asian participant populations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INDUSATUMAB VEDOTIN | Unknown | 1.2 mg/kg | Intravenous |
| Subject | INDUSATUMAB VEDOTIN | Unknown | 1.5 mg/kg | Intravenous |
| Subject | INDUSATUMAB VEDOTIN | Unknown | 1.8 mg/kg | Intravenous |